The cancer stem cell subtype determines immune infiltration of Glioblastoma

Stem Cells and Development

Volumn 21, Issue 15, 2012, Pages 2753-2761

  Beier, Christoph P ^a,b   Kumar, Praveen ^a,b,c   Meyer, Katharina ^c   Leukel, Petra ^c   Bruttel, Valentin ^d   Aschenbrenner, Ines ^c   Riemenschneider, Markus J ^e   Fragoulis, Athanassios ^f   Rümmele, Petra ^c   Lamszus, Katrin ^g   Schulz, Jörg B ^a,b   Weis, Joachim ^b,f   Bogdahn, Ulrich ^c   Wischhusen, Jörg ^d   Hau, Peter ^c   Spang, Rainer ^c   Beier, Dagmar ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b JARA TRANSLATIONAL BRAIN MEDICINE   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f RWTH AACHEN UNIVERSITY   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; SMAD2 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOLOGIC FACTORS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SMAD2 PROTEIN; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TUMOR BURDEN;

EID: 84870439234     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0660     Document Type: Article

References (20)

1. Li A, J Walling, S Ahn, Y Kotliarov, Q Su, M Quezado, JC Oberholtzer, J Park, JC Zenklusen and HA Fine. (2009). Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 69:2091-2099.
2. Huse JT, HS Phillips and CW Brennan. (2011). Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 59:1190-1199.
3. Phillips HS, S Kharbanda, R Chen, WF Forrest, RH Soriano, TD Wu, A Misra, JM Nigro, H Colman, et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173.
4. Verhaak RG, KA Hoadley, E Purdom, V Wang, Y Qi, MD Wilkerson, CR Miller, L Ding, T Golub, et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
5. Brennan C, H Momota, D Hambardzumyan, T Ozawa, A Tandon, A Pedraza and E Holland. (2009). Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4:e7752.
6. Gunther HS, NO Schmidt, HS Phillips, D Kemming, S Kharbanda, R Soriano, Z Modrusan, H Meissner, M Westphal and K Lamszus. (2008). Glioblastoma-derived stem cellenriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897-2909.
7. Beier D, P Hau, M Proescholdt, A Lohmeier, J Wischhusen, PJ Oefner, L Aigner, A Brawanski, U Bogdahn and CP Beier. (2007). CD133 + and CD133-glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010-4015.
8. Lottaz C, D Beier, K Meyer, P Kumar, A Hermann, J Schwarz, M Junker, PJ Oefner, U Bogdahn, et al. (2010). Transcriptional profiles of CD133 + and CD133-glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70:2030-2040.
9. Prins RM, H Soto, V Konkankit, SK Odesa, A Eskin, WH Yong, SF Nelson and LM Liau. (2011). Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603-1615.
10. Weller M and A Fontana. (1995). The failure of current immunotherapy for malignant glioma. Tumor-derived TGFbeta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 21:128-151.
11. Schraivogel D, L Weinmann, D Beier, G Tabatabai, A Eichner, JY Zhu, M Anton, M Sixt, M Weller, CP Beier and G Meister. (2011). CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells. EMBO J 30:4309-4322.
12. Eisele G, J Wischhusen, M Mittelbronn, R Meyermann, I Waldhauer, A Steinle, M Weller and MA Friese. (2006). TGFbeta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 129:2416-2425.
13. Murat A, E Migliavacca, T Gorlia, WL Lambiv, T Shay, MF Hamou, N de Tribolet, L Regli, W Wick, et al. (2008). Stem cell-related "self- renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015-3024.
14. Lee J, S Kotliarova, Y Kotliarov, A Li, Q Su, NM Donin, S Pastorino, BW Purow, N Christopher, et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391-403.
15. Pollard SM, K Yoshikawa, ID Clarke, D Danovi, S Stricker, R Russell, J Bayani, R Head, M Lee, et al. (2009). Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4:568-580.
16. Penuelas S, J Anido, RM Prieto-Sanchez, G Folch, I Barba, I Cuartas, D Garcia-Dorado, MA Poca, J Sahuquillo, J Baselga and J Seoane. (2009). TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15:315-327.
17. Hannigan A, P Smith, G Kalna, C Lo Nigro, C Orange, DI O'Brien, R Shah, N Syed, LC Spender, et al. (2010). Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest 120:2842-2857.
18. Friese MA, J Wischhusen, W Wick, M Weiler, G Eisele, A Steinle and M Weller. (2004). RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64:7596-7603.
19. Uhl M, S Aulwurm, J Wischhusen, M Weiler, JY Ma, R Almirez, R Mangadu, YW Liu, M Platten, et al. (2004). SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64:7954-7961.
20. Schwartzbaum JA, K Huang, S Lawler, B Ding, J Yu and EA Chiocca. (2010). Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol 12:320-327.